SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended

 

March 31, 2004

 

Commission file number 0-19878

 

 

OPTION CARE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware		36-3791193
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)
485 Half Day Road, Suite 300 Buffalo Grove, Illinois		60089
(Address of principal executive office)		(zip code)
(847) 465-2100
(Registrant’s telephone number, including area code)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý  No o

 

Indicate by check mark whether the registrant is an accelerated filer (as defined in Exchange Act Rule 12b-2). Yes ý  No o

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

	Class		Issued and Outstanding as of  May 5, 2004
	Common Stock - .01 par value		21,293,317

 

 

INDEX

 

OPTION CARE, INC. AND SUBSIDIARIES

 

DESCRIPTION
PART I	FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)
	Condensed consolidated balance sheets—March 31, 2004 and December 31, 2003
	Condensed consolidated statements of operations—Three months ended March 31, 2004 and 2003
	Condensed consolidated statements of cash flows—Three months ended March 31, 2004 and 2003
	Notes to condensed consolidated financial statements—March 31, 2004
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations
Item 3.	Quantitative and Qualitative Disclosures about Market Risk
Item 4.	Controls and Procedures
PART II	OTHER INFORMATION
Item 1.	Legal Proceedings
Item 2.	Changes in Securities and Use of Proceeds
Item 3.	Defaults Upon Senior Securities
Item 4.	Submission of Matters to a Vote of Security Holders
Item 5.	Other Information
Item 6(a).	Exhibits
Item 6(b).	Reports on Form 8-K
SIGNATURES

 

2

 

PART I.  FINANCIAL INFORMATION

 

Item 1.  Financial Statements

 

Option Care, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except per share amounts)

 

		March 31, 2004			December 31, 2003
		(Unaudited)			(Note 1)
Assets
Current assets:
Cash and cash equivalents		$	6,649		$	3,961
Accounts receivable, net		65,721			62,190
Inventory		8,248			11,522
Deferred income tax benefit		3,976			4,442
Other current assets		4,218			5,279
Total current assets		88,812			87,394
Equipment and other fixed assets, net		12,176			12,145
Goodwill, net		65,661			64,970
Other assets		1,874			2,025
Total assets		$	168,523		$	166,534
Liabilities and stockholders’ equity
Current liabilities:
Trade accounts payable		$	18,523		$	19,940
Current portion of long-term debt		112			424
Other current liabilities		9,054			10,253
Total current liabilities		27,689			30,617
Long-term debt, less current portion		29			82
Long-term deferred income tax liability		5,983			5,677
Other liabilities		702			711
Minority interest		468			427
Total liabilities		34,871			37,514
Stockholders’ equity:
Common stock, $.01 par value per share, 60,000 shares authorized, 21,232 and 20,942 shares issued and outstanding at March 31, 2004 and December 31, 2003, respectively		212			209
Common stock to be issued, 27 and 144 shares at March 31, 2004 and December 31, 2003, respectively		276			834
Additional paid-in capital		106,019			104,173
Retained earnings		28,250			23,965
Less treasury stock, at cost, common shares 101 and 15, respectively		(1,105		)	(161		)
Total stockholders’ equity		133,652			129,020
Total liabilities and stockholders’ equity		$	168,523		$	166,534

 

See notes to condensed consolidated financial statements

 

3

 

Option Care, Inc. and Subsidiaries

Condensed Consolidated Statements of Income

(Unaudited)

(in thousands, except per share amounts)

 

		Three months ended March 31,
		2004			2003
Revenue:
Specialty pharmacy services		$	64,932		$	57,034
Infusion and related healthcare services		34,946			33,073
Other		3,271			2,455
Total revenue		103,149			92,562
Cost of revenue:
Cost of goods sold		63,808			54,824
Cost of services provided		10,644			10,458
Total cost of revenue		74,452			65,282
Gross profit		28,697			27,280
Selling, general and administrative expenses		19,249			18,030
Provision for doubtful accounts		1,559			1,878
Depreciation and amortization		681			668
Total operating expenses		21,489			20,576
Operating income		7,208			6,704
Interest income (expense)		1			(99		)
Other expense, net		(67		)	(9		)
Income before income taxes		7,142			6,596
Income tax provision		2,857			2,630
Net income		$	4,285		$	3,966
Net income per common share:
Basic		$	0.20		$	0.19
Diluted		$	0.20		$	0.19
Shares used in computing net income per share:
Basic		21,091			20,807
Diluted		21,556			21,156

 

See notes to condensed consolidated financial statements

 

4

 

Option Care, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

 

		Three Months Ended March 31,
		2004			2003
Cash flows from operating activities:
Net income		$	4,285		$	3,966
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		1,204			1,069
Provision for doubtful accounts		1,559			1,878
Deferred income taxes		806			750
Income tax benefit from exercise of stock options		456			52
Changes in assets and liabilities:
Accounts receivable		(4,709		)	(4,784		)
Inventory		3,342			581
Accounts payable		(1,417		)	335
Income taxes receivable/payable		1,331			1,089
Change in other assets and liabilities		(1,631		)	(266		)
Net cash provided by operating activities		5,226			4,670
Cash flows from investing activities:
Purchases of equipment and other, net		(975		)	(1,390		)
Payments for acquisitions, net of cash acquired		(1,090		)	(3,058		)
Proceeds from disposals		—			84
Net cash used in investing activities		(2,065		)	(4,364		)
Cash flows from financing activities:
Net borrowing on credit agreements		—			43
Payments on capital leases and other debt		(364		)	(80		)
Proceeds from issuance of stock		835			317
Payments for purchase of treasury stock		(944		)	—
Net cash provided by (used in) financing activities		(473		)	280
Net increase in cash and cash equivalents		2,688			586
Cash and cash equivalents, beginning of period		3,961			488
Cash and cash equivalents, end of period		$	6,649		$	1,074

 

See notes to condensed consolidated financial statements

 

5

 

Option Care, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

March 31, 2004

(Unaudited)

 

1.   Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2004 are not necessarily indicative of the results that may be expected for the year ending December 31, 2004.

 

The balance sheet at December 31, 2003 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

 

For further information, refer to the consolidated financial statements and footnotes thereto included in Option Care’s Annual Report on Form 10-K for the year ended December 31, 2003.

 

2.   Long-Term Debt

 

We entered into a three-year, $60 million revolving Credit and Security Agreement on March 29, 2002 with J.P. Morgan Business Credit Corporation, J.P. Morgan Chase Bank and LaSalle Bank, N.A. (the “Lenders”).  Availability under the Credit and Security Agreement is related to various percentages of our outstanding accounts receivable and inventory balances, less certain capped and ineligible amounts, as defined in the agreement.  Overall borrowings under the agreement will be limited to the lesser of the remaining availability and the total allowable collateral borrowing base.  The facility is secured by substantially all company assets.  In addition to customary events of default, the facility provides that a change in control would give rise to an event of default. The facility requires us to meet certain financial covenants.  We paid a facility fee of approximately $400,000 upon signing the agreement.  The agreement provides for a commitment fee, calculated and paid quarterly on a sliding scale from 0.45% to 0.25%, based on the average daily unused portion of the facility.  For a fee, we may secure up to $5 million in letters of credit.  Depending on our level of borrowing under the agreement, we may select interest rates ranging from the Eurodollar Rate plus 2% to 2.75%, or the bank’s reference rate plus 0% to 0.75%.  The agreement is scheduled to expire on March 29, 2005.

 

As of March 31, 2004 and December 31, 2003, we had no balance outstanding under this facility.   At March 31, 2004, we had borrowing availability of $38.4 million based on the accounts receivable and inventory balances as of that date, while at December 31, 2003 we had additional borrowing capacity of $37.7 million.

 

On October 23, 2003, the Lenders and Option Care signed an amendment to the Credit and Security Agreement to address the $6.8 million special provision for doubtful accounts recorded in the quarter ended September 30, 2003 related to our Texas accounts receivable.  The amendment allows us to exclude the $6.8 million charge when calculating our fixed charge coverage ratio in the current and subsequent quarters.  This change in calculation method allowed us to remain in compliance with our financial covenants for the quarters ended September 30 and December 31, 2003.  For the quarter ended March 31, 2004, we were in compliance with our financial covenants before consideration of the amendment.

 

6

 

3.    Earnings Per Share Data

 

The following table sets forth the computation of basic and diluted earnings per share for the periods indicated (in thousands, except per share amounts):

 

		Three months ended March 31,
		2004			2003
Basic:
Net income		$	4,285		$	3,966
Average shares outstanding		21,091			20,807
Basic earnings per share		$	0.20		$	0.19
Diluted:
Net income		$	4,285		$	3,966
Average shares outstanding		21,091			20,807
Net effect of dilutive stock options – Based on the treasury stock method		465			349
Total diluted shares		21,556			21,156
Diluted earnings per share		$	0.20		$	0.19

 

4.   Operating Segments

 

Option Care has one identifiable business segment, with three service lines: specialty pharmacy services; infusion and related healthcare services; and other.  Specialty pharmacy services involve the distribution of injectible and infused pharmaceuticals to treat a wide range of chronic health conditions.  The pharmaceuticals can be directly distributed to the patient’s home or to their physician’s office for in-office administration.  These pharmaceuticals may require refrigeration during shipping as well as special handling to prevent potency degradation.  Patients receiving treatment usually require special counseling and education regarding their condition and treatment program.  Infusion and related healthcare services primarily involves the intravenous administration of medications at the patient’s home or other non-hospital sites such at one of our infusion suites.  Infusion pharmacy services treat a wide range of acute and chronic health conditions, including infections, dehydration, cancer, pain and nutritional deficiencies.  All of our company-owned pharmacies provide infusion pharmacy services.  Some of these pharmacies also provide related healthcare services, such as home health nursing, home hospice services, respiratory therapy services and durable medical equipment.  Other revenue consists of royalties and other fees generated from our franchised pharmacy network and the software licensing and support revenue generated by our subsidiary, Management by Information, Inc. (“MBI”).

 

7

 

The following table presents revenues from external customers for each service line, broken down by major product category, for the periods indicated (in thousands):

 

		Three months ended March 31,
		2004			2003
Specialty pharmacy services		$	64,932		$	57,034
Infusion and related healthcare services:
Infusion therapy		29,642			27,233
Related healthcare services		5,304			5,840
Total infusion and related healthcare services revenue		34,946			33,073
Other revenue:
Franchise-related		2,899			2,144
Software licensing and support		372			311
Total other revenue		3,271			2,455
Total revenue		$	103,149		$	92,562

 

5.   Significant Customers and Concentration of Credit Risk

 

The following table sets forth information regarding revenue and accounts receivable related to our most significant payors as of the dates and for the periods presented:

 

		Revenue				Accounts Receivable
		Three months ended March 31,				March 31, 2004		December 31, 2003
		2004		2003
Blue Cross and Blue Shield of Florida		15	%	17	%	7	%	9	%
Medicare		7	%	7	%	9	%	10	%
Medicaid		13	%	11	%	9	%	10	%
Total – government payors		20	%	18	%	18	%	20	%
All other payors (1)		65	%	65	%	75	%	71	%
Total		100	%	100	%	100	%	100	%

 

(1) No other payor represents 10% or more of revenue or accounts receivable as of the dates and for the periods presented.

 

We generate the majority of our revenue from managed care contracts and other agreements with commercial third party payors from our provision of health care services to their members.  Our principal managed care contract is with Blue Cross and Blue Shield of Florida, to whose members we provide infusion pharmacy services and specialty pharmacy services.  For the three months ended March 31, 2004 and 2003, respectively, 15% and 17% of our revenue was related to this contract.  As of March 31, 2004 and December 31, 2003, 7% and 9% of our accounts receivable, respectively, was due from Blue Cross and Blue Shield of Florida.  The contract is terminable by either party on 90 days’ notice and, unless terminated, renews annually each September for an additional one-year term.

 

Option Care also generates revenue from government healthcare programs such as Medicare and Medicaid.  For the three months ended March 31, 2004 and 2003, respectively, 20% and 18% of our revenue came from government healthcare programs. Of our total accounts receivable as of March 31, 2004 and December 31, 2003, approximately 18% and 20%, respectively, was due from government healthcare programs.

 

8

 

6.   Seasonal Revenue Trends

 

Synagis®, one of the specialty pharmaceuticals that we provide to patients, is seasonal.  Synagis® is a drug used for the prevention of respiratory synctial virus (RSV) in high-risk pediatric patients. RSV infection is a seasonal condition, with the season generally lasting from October through April.

 

 Option Care’s quarterly Synagis® revenue for 2003 and the first quarter of 2004 was as follows (amounts in thousands):

 

		Synagis® revenue			% of Specialty Pharmacy Revenue		% of Total Revenue
Quarter ended March 31, 2003		$	11,998		21.0	%	13.0	%
Quarter ended June 30, 2003		3,958			8.2	%	4.7	%
Quarter ended September 30, 2003		435			0.9	%	0.5	%
Quarter ended December 31, 2003		8,867			15.5	%	9.3	%
Fiscal year 2003		$	25,258		12.1	%	7.1	%
Quarter ended March 30, 2004		$	14,251		21.9	%	13.8	%

 

7.   Acquisitions

 

During the quarter ended March 31, 2004, we completed two small acquisitions through asset purchase agreements.  We consolidated the results of the newly acquired businesses as of the dates they were acquired.

 

On January 13, 2004, we acquired certain assets and the respiratory therapy and durable medical equipment (RT/DME) business of JCMG Ancillary Services, a provider located in Jefferson City, Missouri.  This acquisition increased our RT/DME market share in central Missouri.  Management of the operations of this business was immediately consolidated with that of our existing pharmacy, hospice and RT/DME business located in Columbia, Missouri.  The total purchase price was $565,000, paid in cash.

 

On January 22, 2004, we acquired certain assets and the infusion pharmacy business of our franchise in Upper Darby, Pennsylvania.  This acquisition consolidates our presence in the Philadelphia area, as the territory served by this franchise was adjacent to the territory of one of our company-owned pharmacies.  We consolidated the operations of this business with our existing Philadelphia area pharmacy immediately upon consummating the agreement.  The total purchase price was $725,000, of which $525,000 was paid in cash at closing and $200,000 will be payable in future periods, subject to certain contingencies regarding collection of purchased accounts receivable.

 

The following table presents our allocation of the total purchase price for these acquisitions (in thousands):

 

Accounts receivable, net		$	368
Inventory		68
Equipment and other fixed assets		85
Goodwill		691
Other intangible assets		78
Total purchase price		1,290
Less deferred purchase price liability		(200		)
Total cash paid in the quarter ended March 31, 2004		$	1,090

 

9

 

8.   Stock-based Compensation

 

Statement of Financial Accounting Standards No. 123, Accounting for Stock-Based Compensation, as amended by Statement of Financial Accounting Standards No. 148, Accounting for Stock-Based Compensation—Transition and Disclosure, encourages, but does not require, companies to record compensation cost for stock-based compensation plans at fair value.  Option Care has chosen to account for stock-based compensation using the intrinsic value method prescribed in Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees, and related interpretations.  Accordingly, compensation expense for stock options is measured as the excess, if any, of the quoted market price of Option Care stock at the date of grant over the amount an employee must pay to acquire the stock.  Option Care grants options at fair market value and therefore recognizes no compensation expense when options are granted.  Likewise, Option Care’s Employee Stock Purchase Plan was structured to qualify under Section 423 of the Internal Revenue Code.  Therefore, no compensation expense is recognized from employees’ purchase of shares under our Employee Stock Purchase Plan.

 

Had compensation cost for Option Care’s stock-based compensation plan been determined based on FASB Statement No. 123, Option Care’s net income and income per common share for the three months ended March 31, 2004 and 2003 on a pro-forma basis would have been (in thousands, except per share amounts):

 

		Three months ended March 31,
		2004			2003
Net income:
As reported		$	4,285		$	3,966
Deduct: Total stock-based employee compensation expense determined under the fair value based method for the following awards, net of related tax effects:
Stock option grants		(332		)	(573		)
Employee stock purchase plan withholdings		(35		)	(53		)
Pro forma		$	3,918		$	3,340
Net income per common share-basic:
As reported		$	0.20		$	0.19
Pro forma		$	0.19		$	0.16
Net income per common share-diluted:
As reported		$	0.20		$	0.19
Pro forma		$	0.18		$	0.16

 

9.   Comprehensive Income

 

Net income was our only component of comprehensive income for the quarters ended March 31, 2004 and 2003.

 

10

 

Item 2.                                     Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

FORWARD LOOKING STATEMENTS

 

The following discussion should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2003. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this Quarterly Report on Form 10-Q and other materials filed or to be filed by us with the Securities and Exchange Commission (as well as information included in oral statements or other written statements made or to be made by us) contain statements that are or will be forward-looking, such as statements relating to acquisitions and other business development activities, future capital expenditures and the effects of future regulation and competition. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by us, or on our behalf. These risks and uncertainties include, but are not limited to, uncertainties affecting our businesses and our franchisees relating to acquisitions and divestitures (including continuing obligations with respect to completed transactions), sales and renewals of franchises, government and regulatory policies (including federal, state and local efforts to reform the delivery of and payment for healthcare services), general economic conditions (including economic conditions affecting the healthcare industry in particular), the pricing and availability of equipment and services, technological developments and changes in the competitive environment in which we operate.

 

OVERVIEW

 

We provide pharmacy services to patients on behalf of managed care organizations and other third party payors.  We contract with payors to provide specialty pharmacy services, infusion pharmacy and other related healthcare services to patients at home or at other alternate-site settings, such as physicians’ offices or infusion suites at our pharmacy locations.  Our services are provided through our national network of company-owned and franchise-owned pharmacies.

 

We have three service lines: specialty pharmacy services, infusion and related healthcare services, and other. Specialty pharmacy services involve the distribution of injectible and infused pharmaceuticals to treat a wide range of chronic health conditions.  The pharmaceuticals can be directly distributed to the patient’s home or to their physician’s office for in-office administration.  These pharmaceuticals may require refrigeration during shipping as well as special handling to prevent potency degradation.  Patients receiving treatment usually require special counseling and education regarding their condition and treatment program.  Infusion and related services primarily involves the intravenous administration of medications at the patient’s home or other non-hospital site such as one of our infusion suites.  Infusion pharmacy services treat a wide range of acute and chronic health conditions, including infections, dehydration, cancer, pain and nutritional deficiencies.  All of our company-owned pharmacies provide infusion therapies.  Some of these pharmacies also provide related healthcare services, such as home health nursing, home hospice services, respiratory therapy services and durable medical equipment.  Other revenue consists of royalties and other fees generated from our franchised pharmacy network and the software licensing and support revenue generated by our subsidiary, MBI.

 

Summarized information about revenues and gross profit for each service line is provided in the following table (amounts in thousands):

 

		Three months ended March 31, 2004										Three months ended March 31, 2003
		Revenue			% of total		Gross Profit			Gross profit%		Revenue			% of total		Gross Profit			Gross profit%
Specialty pharmacy services		$	64,932		62.9	%	$	10,526		16.2	%	$	57,034		61.6	%	$	11,034		19.3	%
Infusion and related healthcare services		34,946			33.9	%	15,029			43.0	%	33,073			35.7	%	13,879			42.0	%
Other		3,271			3.2	%	3,142			96.1	%	2,455			2.7	%	2,367			96.4	%
Total revenue		$	103,149		100.0	%	$	28,697		27.8	%	$	92,562		100.0	%	$	27,280		29.5	%

 

The majority of our revenue is generated from managed care contracts and other agreements with commercial third party payors.  Our principal managed care contract is with Blue Cross Blue Shield of Florida for the provision of specialty pharmacy services and infusion pharmacy services to their members. For the three months ended March 31, 2004 and 2003, respectively, approximately

 

11

 

15% and 17% of our revenue was generated from this contract.  As of March 31, 2004 and December 31, 2003, respectively, 7% and 9% of our accounts receivable was due from Blue Cross Blue Shield of Florida. The contract is terminable by either party on 90 days’ notice and, unless terminated, renews annually each September for an additional one-year term.

 

We also generate revenue from government healthcare programs such as Medicare and Medicaid.  For the three months ended March 31, 2004 and 2003, approximately 20% and 18% of our revenue, respectively, was generated from government healthcare programs.  As of March 31, 2004 and December 31, 2003, respectively, 18% and 20% of our total accounts receivable was due from these government healthcare programs.

 

Many of the pharmaceuticals we provide are reimbursed at some percentage of the Average Wholesale Price (AWP) for those pharmaceuticals.  AWP for most pharmaceuticals is compiled and published by private companies, including First DataBank, Inc.  In recent years, we have seen reductions to AWP for certain of the pharmaceuticals that we provide to patients in the aftermath of government investigations and other legal and regulatory actions.  Any modifications to the AWP system or reductions in AWP for the products we provide to patients could narrow our gross profit margins.

 

The Medicare Prescription Drug, Improvement and Modernization Act of 2003 changed the way in which covered outpatient drugs are reimbursed by the Medicare program.  Starting in January 2004, payment for most drugs covered by Medicare will decrease to 85% of the AWP for those drugs, determined as of April 1, 2003.  Beginning in 2005, reimbursement for non-self administered drugs furnished to patients in conjunction with other Medicare covered services will be set at either 106% of the average sales price (ASP) or through a competitive acquisition program to be phased in beginning in 2006.  For infusion drugs administered in connection with covered durable medical equipment, the payment rate generally will continue to be 95% of the AWP as of October 1, 2003, until such drugs are subject to the implementation of a competitive acquisition program.  While the majority of our revenue is reimbursed by managed care organizations and other non-government payors, these changes to the way in which Medicare pays for outpatient drugs and biologicals may have some impact on us or our franchisees.  In addition, as the Center for Medicare and Medicaid Services (CMS) implements the ASP reimbursement model, managed care organizations may push for adoption of ASP as the basis of pharmaceutical reimbursement as well.  If managed care organizations do adopt the ASP model, our future financial condition and results of operations could be materially affected based on our ability to renegotiate pricing using the ASP methodology.

 

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

 

Management’s discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and their related disclosures. On an ongoing basis, Option Care evaluates its estimates and judgments based on historical experience and various other factors that are believed to be reasonable. Actual results may vary from these estimates under different assumptions or conditions. We annually review our financial reporting and disclosure practices and accounting policies to ensure that our financial reporting and disclosures provide accurate and transparent information relative to our financial condition and results of operations, as well as our current business environment. Option Care management believes that of our significant accounting policies, the following policies involve a higher degree of judgment and/or complexity.

 

Revenue recognition and contractual adjustments

 

Our revenue is primarily derived from the sale of pharmaceuticals and medical supplies and the provision of related nursing services to patients outside the hospital at alternate-site settings. Most of this revenue is billed under managed care or other contracts, with a smaller amount billed under government healthcare programs, such as Medicare and Medicaid. We bill upon receipt of all required documentation from payors, physicians and our staff. At the end of any period, a portion of our earned revenue remains unbilled awaiting completion of all documentation requirements. Billed and unbilled revenue is recorded net of contractual adjustments based on our interpretation of the terms of each managed care contract or government contract or pricing schedule, as loaded into our computerized billing and pharmacy management software systems. In most cases, our contractual adjustments are calculated automatically by our billing system when the claim is billed, subject to review by the biller. If our billing system cannot automatically generate the contractual adjustment for a given claim, we calculate the contractual adjustment manually and key the adjustment into our billing system when the claim is billed. The contractual adjustments on unbilled amounts must be estimated manually through

 

12

 

claim-by-claim analysis of the unbilled claims, by applying historical contractual adjustment percentages to the gross unbilled amounts, or a combination of the two methods. The accuracy of our recorded net revenue is subject to the accuracy of payor information on file for each patient, and is also subject to our correct interpretation of each underlying contract with respect to reimbursement rates for the drugs and services we provided. If changes or corrections to our estimates of net revenue prove to be necessary, we adjust net revenue in the period that such changes or corrections are identified. Such adjustments may have a positive or negative impact on the revenues and results of operations reported for those subsequent periods. Historically, such adjustments have not been significant to our statements of income.

 

Accounts receivable and allowances for doubtful accounts

 

Our accounts receivable are reported net of contractual adjustments and allowances for doubtful accounts. The majority of our accounts receivable are due from private insurance carriers and government healthcare programs such as Medicare or Medicaid. Third party reimbursement is a complicated process, with each payor having its own claim requirements. The ultimate collection of our accounts receivable is dependent upon complete and accurate patient intake, timely submission of clean claims to payors, and timely and effective follow-up on outstanding claims. Our collection process involves multiple steps. The first step is to bill each claim correctly, with proper coding, after having received all prerequisite authorizations from the patient’s physician and insurance company, as applicable. For claims submitted electronically, we receive electronic acceptance of the claim from the insurance company or governmental agency responsible for paying the claim. This helps to assure collection of the account. For mailed insurance claims or those for which electronic confirmation of acceptance is unavailable, the billing staff member responsible for that claim will contact the payor if payment is not received promptly. The billing staff member will inquire as to the status of the claim, and will re-bill the claim or provide additional information as requested by the payor. Upon rebilling, the billing staff member will contact the payor to confirm receipt of the re-billed claim, and will follow up periodically until payment is received.

 

We write off accounts receivable as bad debts after all collection efforts have been exhausted, according to the following procedures. Our billing staff members review the status of their unpaid claims on a regular basis. During that review, the billing staff member will identify the reason for non-payment of a given claim. Should the reason relate to a correctable error with the claim itself, or incomplete or inadequate documentation provided to the payor, the billing staff member will attempt to address those issues and re-submit a corrected claim or provide additional information to the payor, as appropriate. In the event the claim error or documentation error cannot be corrected, the allowed time to correct and re-submit the claim has expired, or the claim is not paid due to a payor-related issue such as bankruptcy, the billing staff member will submit a formal request for write-off. The appropriate supervisor will review the request and authorize the claim to be written off if that supervisor agrees that the account is truly uncollectable. The identity of the appropriate supervisor to authorize a write-off is determined based on the reporting structure within each office and based on the dollar amount to be written off, with higher-level authorization required for larger dollar write-offs.

 

Our allowance for doubtful accounts is estimated based on several factors, including our past accounts receivable collection history, the aging of our accounts receivable at the end of each period as reported to us through our computerized billing systems, our mix of business, and the financial condition of our payors. We evaluate historical write-off percentages by aging category to help us determine the appropriate reserve needed at each balance sheet date based on the aging of our receivables at that date. We also take into account certain internal factors, such as computer systems conversions, office acquisitions and consolidations, and operational changes within our billing and reimbursement function. Although we believe that our estimation of the net value of our accounts receivable is reasonable, we continually monitor our accounts receivable and our methods for calculating the appropriate allowance for doubtful accounts, and we adjust our allowances and calculation methods as needed. If actual collections differ from our estimates, we may need to establish an additional allowance for doubtful accounts, which could materially impact our financial condition and results of operations in future periods.

 

Goodwill and other intangible assets

 

We record goodwill from our acquisitions equal to the excess of the total cost of the acquisitions over the fair value of all identified tangible and intangible assets acquired. In accordance with Statement of Financial Accounting Standards (SFAS) No. 142, Goodwill and Intangible Assets, effective January 1, 2002 we no longer amortize goodwill but instead test our goodwill at least annually for impairment. Since we operate in one business segment, we test for goodwill impairment on a company-wide basis. Therefore, our method of impairment testing consists of comparing the market value of our company to its book value. The market value is equal to the current value per share of our common stock, times the total number of shares outstanding. We test goodwill for impairment

 

13

 

annually each October 1st, or whenever we identify events or conditions that could potentially result in impairment of our goodwill.

 

Other intangible assets primarily consist of non-compete agreements and managed care contracts. These intangible assets are amortized straight-line over periods ranging from two to five years. Their amortization period equals their estimated useful lives, or in the case of non-compete agreements, the amortization period equals their contractual term.

 

Computer software developed costs

 

 Software developed for sale to external customers

 

Our subsidiary, MBI, has internally developed a computer software program, iEmphsys, designed specifically for management of home infusion pharmacy businesses. iEmphsys has been designed both for external sale to independent home infusion businesses and for internal use by our company-owned pharmacies.

 

We account for software designed for sale to external customers in accordance with Statement of Financial Accounting Standard No. 86 (SFAS No. 86)—Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed. Accordingly, the costs incurred subsequent to establishing technological feasibility for the software program have been capitalized. These costs include coding and testing performed subsequent to establishing technological feasibility. Capitalization of the software program costs ceased when the product became available for general release to customers.

 

The annual amortization expense for the software program is computed using the greater of (a) the amount computed using the ratio that current gross revenues for a product bear to the total of current and anticipated future gross revenues for that product or (b) the straight-line method over the remaining estimated life of the product, including the period being reported on. At each balance sheet date, the unamortized capitalized costs of the software program are compared to its net realizable value. If the estimated net realizable value of the software program exceeds its unamortized capitalized costs, we will write off the amount by which the unamortized capitalized costs exceeds the net realizable value.

 

Software developed for internal use only

 

We have developed and are developing various software products designed only for use by us in the operation of our business. Such software development projects are accounted for in accordance with Statement of Position 98-1 (SOP 98-1)—Accounting for the Costs of Computer Software Developed or Obtained for Internal Use, issued by the Accounting Standards Executive Committee of the American Institute of Certified Public Accountants (AICPA). We account for software development costs for internal-use software according to the following criteria:

 

(a)  Computer software costs that are incurred in the preliminary project stage are expensed;

 

(b)  Once the capitalization criteria under the SOP have been met, external direct costs of materials and services consumed in developing or obtaining internal-use computer software; payroll and payroll-related costs for employees who are directly associated with and who devote time to the internal-use computer software project; and interest costs incurred when developing computer software for internal use are capitalized and;

 

(c)  Once the product is operative, internal and external training costs and maintenance costs are expensed as incurred.

 

We amortize capitalized costs of computer software developed or obtained for internal use on a straight-line basis over the estimated useful life of the software. We will recognize impairment on the capitalized computer software developed for internal use, if one of the following conditions is present:

 

(a)  The internal use software is not expected to provide substantive service potential,

 

(b)  A significant change occurs in the extent or manner in which the software is used or is expected to be used,

 

14

 

(c)  A significant change is made or will be made to the software program, and

 

(d)  Costs of developing or modifying internal-use computer software significantly exceed the amount originally expected to develop or modify the software.

 

15

 

RESULTS OF OPERATIONS

 

The following table shows the results of our operations for the three months ended March 31, 2004 and 2003, expressed in amounts and percentages of revenue (amounts in thousands):

 

		Three Months Ended March 31, 2004					Three months Ended March 31, 2003
		Amount			% of Revenue		Amount			% of Revenue
Revenue:
Specialty pharmacy services		$	64,932		62.9	%	$	57,034		61.6	%
Infusion and related healthcare services		34,946			33.9	%	33,073			35.7	%
Other		3,271			3.2	%	2,455			2.7	%
Total revenue		103,149			100.0	%	92,562			100.0	%
Cost of revenue:
Cost of goods sold		63,808			61.9	%	54,824			59.2	%
Cost of services provided		10,644			10.3	%	10,458			11.3	%
Total cost of revenue		74,452			72.2	%	65,282			70.5	%
Gross profit		28,697			27.8	%	27,280			29.5	%
Selling, general and administrative expenses		19,249			18.7	%	18,030			19.5	%
Provision for doubtful accounts		1,559			1.5	%	1,878			2.0	%
Depreciation and amortization		681			0.6	%	668			0.8	%
Total operating expenses		21,489			20.8	%	20,576			22.3	%
Operating income		7,208			7.0	%	6,704			7.2	%
Interest expense		1			—	%	(99		)	(0.1	)%
Other income (expense), net		(67		)	(0.1	)%	(9		)	—	%
Income before income taxes		7,142			6.9	%	6,596			7.1	%
Income tax provision		2,857			2.7	%	2,630			2.8	%
Net income		$	4,285		4.2	%	$	3,966		4.3	%

 

Three Months Ended March 31, 2004 and 2003

 

We achieved record revenue of $103.1 million and net income of $4.3 million during the quarter ended March 31, 2004.  These figures represent increases of 11.4% and 8.0% over our revenue and net income from the corresponding prior year quarter.  Net income per diluted share was $0.20 for the quarter ended March 31, 2004 compared to $0.19 in the prior year quarter.  The revenue increase was attributable to strong organic growth in infusion pharmacy and specialty pharmacy services, with the largest increases from seasonal sales of Synagis® as well as from Xolair®, a specialty drug recently approved for the treatment of moderate to severe allergic asthma.  Our renewed and refocused sales efforts in recent months contributed to our overall revenue growth.

 

Our days sales outstanding (DSO) dropped to 57 days as of March 31, 2004 compared to 61 days at December 31, 2003 due to continued improvements in cash collections and billing practices.  We ended the quarter with $6.6 million in cash reserves compared to $4.0 million at December 31, 2003.  As of March 31, 2004, we had no outstanding balance on our credit facility and virtually no debt.

 

As sales of Synagis® decline cyclically in the quarter ending June 30, 2004, we intend to focus on maintaining our growth rate for both home infusion and specialty pharmacy services.  We plan to continue to drive improvements in our operations, focusing on purchasing leverage, controlling our operating expenses and continuing to improve our accounts receivable management.   We will also continue to evaluate potential strategic acquisition opportunities designed to enhance our future growth in revenue and net income.

 

16

 

Revenue:

We report our operating results in one segment, consisting of three service lines: specialty pharmacy services; infusion and related healthcare services; and other.  Revenue for the quarter ended March 31, 2004 was $103.1 million, which represents an increase of $10.6 million, or 11.4%, over the prior year quarter.  This revenue increase is primarily due to our $7.9 million increase in specialty pharmacy services revenue and $1.9 million increase in infusion and related healthcare services revenue during the period due to increased sales efforts for existing products and sales generated from a new specialty pharmaceutical.

 

Specialty pharmacy services revenue:

For the quarter ended March 31, 2004, our specialty pharmacy services revenue was $64.9 million, which represents an increase of $7.9 million, or 13.8%, over the prior year quarter.  On a same store basis, factoring out disposal and acquisition activities, the specialty pharmacy services revenue growth rate was 15.3%. The overall $7.9 million increase was primarily attributable to higher sales of Synagis® and human growth hormone, as well as increased sales of Xolair®, a recently-approved drug for the treatment of moderate to severe allergic asthma that is not adequately controlled by the use of inhaled corticosteroids.  In addition, our revenue from our Florida specialty pharmacies also increased compared to the prior year.  Our Synagis® revenue reached $14.3 million in the quarter ended March 31, 2004, representing an increase of $2.3 million over the corresponding prior year quarter.  Synagis® is a drug used to prevent respiratory synctial virus (RSV) in premature and other high-risk infants.  RSV is a seasonal condition with the season generally lasting from October through April.  Accordingly, our Synagis® revenue is at its peak in the quarter ending March 31 of each year. Revenue from sales of human growth hormone increased by $1.6 million in the quarter ended March 31, 2004 versus the prior year quarter.  We distribute human growth hormone nationally from our specialty care pharmacy in Ann Arbor, Michigan.  Increased sales efforts focusing on the efficiency and clinical data reporting capabilities of this pharmacy were the main drivers of this increase.  We began to sell Xolair® during the quarter ended September 30, 2003, and have seen steady increases in revenue since then.

 

Infusion and related healthcare services revenue:

For the quarter ended March 31, 2004, infusion and related healthcare services revenue was $34.9 million, an increase of $1.9 million, or 5.7%, over the corresponding prior year quarter.  Infusion pharmacy services increased $2.4 million, or 9.0%, while related healthcare services, such as RT/DME and home health nursing, declined by $500,000, or 9.2%.  The increase in infusion pharmacy services is due to refocused sales efforts put in place as part of the operational restructuring that we completed late in 2003.  Within our mix of infusion therapies, the largest revenue increase was from anti-infective therapies, which represented approximately 38% of our infusion pharmacy services revenue for the quarter ended March 31, 2004.  On a same store basis, factoring out disposal and acquisition activities, infusion pharmacy services increased by 10.6% in the current year over the corresponding prior year quarter.  The $500,000 decrease in other related healthcare services was primarily due to our decision to scale back our provision of home health nursing services, particularly in markets exhibiting low profitability for these services, and focus instead on growing our core businesses of specialty pharmacy services and infusion pharmacy services.

 

Other revenue:

Other revenue consists of two primary elements: (1) revenue generated from our franchise network, consisting of royalties, franchise fees and vendor rebates earned through our franchises’ purchases under our contracts, and; (2) software licensing and support services provided by our wholly-owned subsidiary, MBI. Other revenue was equal to $3.3 million for the quarter ended March 31, 2004 compared to $2.5 million in the corresponding prior year quarter.  Of this $800,000 increase, $700,000 related to revenue from franchise operations and $100,000 was from software licensing and support revenue.  Of the increase in franchise-related revenue, $400,000 was from the amortization of a non-compete agreement, expiring in May 2004, with the buyers of a former franchise.  The remaining $300,000 was from an increase in royalties and other related fees.  Software licensing and support fees increased by $100,000 as a result of sales of MBI’s new iEmphsys software.

 

Cost of revenue:

Cost of revenue consists of the cost of goods sold and the cost of service provided.  For the quarter ended March 31, 2004, due to the $10.6 million increases in revenue, our cost of revenue increased by $9.2 million, or 14.0%, over the corresponding quarter of the prior year.

 

Cost of goods sold for the quarter ended March 31, 2004 was $63.8 million, or 61.9% of revenue.  In the prior year quarter, cost of goods sold equaled $54.8 million, or 59.2% of revenue.  The $9.0 million increase, year over year, was the result of our $10.6 million increase in revenue during this period.  The increase in cost of goods sold as a percentage of revenue was due to the fact that specialty pharmacy services revenue increased at a faster pace than infusion and related healthcare services revenue.  Specialty pharmacy services revenue has a much higher cost of goods component than infusion and related healthcare services.

 

Cost of service consists of salaries and related costs for employees directly involved in patient care, including pharmacists, nurses, therapists and delivery drivers.  Cost of service also includes the cost of shipping or delivering products and services to the patient.

 

17

 

Cost of service for the quarter ended March 31, 2004 was $10.6 million, or 10.3% of revenue, compared to $10.5 million, or 11.3% of revenue, for the quarter ended March 31, 2003.  The decline in cost of service as a percentage of revenue was anticipated due to an increase in specialty pharmacy revenue, which has a very small service component, along with the decline in home health nursing services, which has a much higher service component.

 

Gross profit margin.  The following table sets forth the gross profit margin for each of our three service lines: specialty pharmacy services; infusion and related healthcare services; and other:

 

		Three months ended March 31,
		2004		2003
Gross profit margin:
Specialty pharmacy services		16.2	%	19.3	%
Infusion and related healthcare services		43.0	%	42.0	%
Other		96.1	%	96.4	%
Overall gross profit margin		27.8	%	29.5	%

 

Our gross profit margin for the quarter ended March 31, 2004 was 27.8% compared to 29.5% for the quarter ended March 31, 2003. This decline in overall margin was primarily due to a shift in service mix toward specialty pharmacy services, which produce a lower gross profit margin than our other services.  The specialty pharmacy services gross profit margin declined from 19.3% to 16.2%.  This decline was primarily related to a shift in mix of products and therapies.  Most of the specialty pharmacy revenue increase was from Synagis®, human growth hormone and Xolair® that are distributed nationally through our specialty care pharmacy in Ann Arbor, Michigan.  These products generate lower profit margins than many of the other specialty pharmaceuticals that we provide to patients.  In addition, we saw increases in specialty pharmacy revenue at our Florida pharmacies, which focus on executing our managed care strategy, producing high sales volume at lower margins under agreements with select managed care partners.  Within the infusion and related healthcare service line, our gross profit margin increased from 42.0% to 43.0% due to changes in therapy mix and our efforts to contain costs through strict purchasing and inventory-handling policies.  Other revenue, which consists of franchise-related revenues and software sales and support, has minimal direct costs and therefore produces a gross profit margin near 100%.

 

Selling, general and administrative expenses:

For the quarter ended March 31, 2004, selling, general and administrative expenses were $19.2 million, an increase of $1.2 million, or 6.8%, over the corresponding prior year quarter.  The expense categories that produced the largest dollar increase were the following: building rent, wages and related costs, recruiting expenses and business insurance costs. Building rent increased by $400,000 primarily due to the relocation of several of our pharmacies during the past twelve months in order to accommodate growth.  Wages and related costs increased by $300,000, or 2.4%, in the quarter ended March 31, 2004 over the prior year quarter. Recruiting expenses increased by $300,000 as we continued to strengthen our human capital by recruiting the strongest possible candidates to manage our operations.  Business insurance costs increased by $200,000 due to the premium increases we experienced at our last annual renewal in June 2003.

 

Provision for doubtful accounts:

Our provision for doubtful accounts for the quarter ended March 31, 2004 was $1.6 million, or 1.5% of revenue, compared to $1.9 million, or 2.0% of revenue, for the corresponding prior year quarter.  The reduction in expense in the current year was due to two main factors: (1) a shift in our mix of business toward products with lower reimbursement risk, and (2) operational improvements that have reduced our bad debt provision requirements at our Texas pharmacies and elsewhere.  Due to the manner of billing and reimbursement for many of the specialty drugs we sell, our risk of non-collection of the related accounts receivable is small.  As our mix of business has shifted toward specialty pharmacy services, our provision for doubtful accounts has decreased accordingly.   In addition to this factor, we have improved and standardized our billing and collection practices throughout our network of company-owned pharmacies, particularly our Texas pharmacies, which has reduced our anticipated incidence of bad debt write-offs.  In the prior year quarter we had recorded much higher provisions in these pharmacies than in the current year quarter.

 

Depreciation and amortization:

For the quarter ended March 31, 2004, depreciation and amortization was $700,000, which was approximately equal to our depreciation and amortization for the corresponding prior year quarter.  The depreciation expense of $500,000 contained within this line item only relates to non-revenue producing assets, such as furniture and fixtures and leasehold improvements.  Depreciation for revenue-producing equipment such as rental medical equipment and delivery vehicles is included in cost of revenue.  Amortization expense of $200,000 relates to intangible assets with finite lives that were obtained through business acquisitions and to the amortization of financing costs related to our credit facility.

 

18

 

Operating income:

Option Care recognized operating income of $7.2 million for the quarter ended March 31, 2004 compared to $6.7 million for the quarter ended March 31, 2003.  This increase in operating income resulted from the increase in revenue in the current year.  As a percentage of revenue, operating income equaled 7.0% for the quarter ended March 31, 2004 compared to 7.2% in the prior year quarter.  The small drop in operating income as a percentage of revenue is related to our increases in specialty pharmacy revenue, which produce a smaller operating margin than our infusion pharmacy and related healthcare services.

 

Interest Income/(Expense):

During the quarter ended March 31, 2004 we had a net positive cash balance and limited borrowing under our credit facility.  Therefore we incurred minimal interest expense during the period which was more than offset by interest income earned from our cash on hand.  During the quarter ended March 31, 2003, we incurred approximately $100,000 in interest expense, which was related to borrowings on our credit facility to finance acquisitions completed in 2002.

 

Income taxes:

For the quarter ended March 31, 2004, our provision for income taxes was $2.9 million compared to $2.6 million in the prior year quarter.  As a percentage of pre-tax income, our provision for income taxes equaled 40.0% in the quarter ended March 31, 2004, virtually unchanged from the 39.9% provision taken in the corresponding prior year quarter.

 

Net income:

Our net income was $4.3 million for the quarter ended March 31, 2004 compared to $4.0 million in the prior year quarter.  Our revenue growth during the period was the primary reason for the increase in net income.

 

Diluted shares & earnings per share:

For the three months ended March 31, 2004, total diluted shares equaled 21.6 million compared to 21.2 million during the corresponding prior year quarter.  The increase was due to issuance of new shares due to stock option exercises and purchases under the employee stock purchase plan, partially offset by our purchase of treasury stock in early January 2004.  Earnings per diluted share equaled $0.20 for the quarter ended March 31, 2004 versus $0.19 in the prior year period, an increase of 5.3%.

 

LIQUIDITY AND CAPITAL RESOURCES

 

During the three months ended March 31, 2004, we financed our operations and acquisition activities through operating cash flows, the use of cash reserves and periodic borrowings under our credit facility.  We continue to generate positive operating cash flows, which strengthened our net cash position during the quarter.

 

Operating Cash Flows:

Operations provided $5.2 million of positive cash flow during the three months ended March 31, 2004 compared to $4.7 million provided by operations during the three months ended March 31, 2003.  The primary causes of our positive operating cash flow for the quarter ended March 31, 2004 were our net income during the period, our improvement in collection of accounts receivable, and our low income taxes paid during the quarter.  Due to strong cash collections during the quarter ended March 31, 2004, our DSO decreased from 61 to 57 days, helping to offset the increase in accounts receivable that resulted from our revenue growth during the quarter.  Income tax payments in the quarter ended March 31, 2004 were minimal, at approximately $300,000, while our tax provision on quarterly earnings was $2.9 million.  We carried a substantial tax overpayment into 2004 due to our net loss in the quarter ended September 30, 2003.  Therefore, in the quarter ended March 31, 2004, we paid no federal income tax installment.

 

Investing Cash Flows.  During the three months ended March 31, 2004, we used cash of $2.1 million in investing activities compared to $4.4 million used during the corresponding prior year quarter.  Of the current year expenditure of $2.1 million, $1.1 million was related to our acquisition of two small businesses in January 2004, one an Option Care franchised pharmacy near Philadelphia and the other an RT/DME provider in central Missouri.  The remaining $1.0 million was used to acquire equipment and other fixed assets.  Of this total, approximately $700,000 was spent on infusion pumps and other revenue-generating medical equipment, $200,000 was spent on infrastructure items such as furniture, fixtures and computer equipment, and $100,000 was spent on ongoing software development projects.

 

Financing Cash Flows:

We used $500,000 in cash for financing activities during the quarter ended March 31, 2004, compared to $300,000 provided by financing activities in the prior year period.  In the current year quarter, we generated $800,000 from the issuance of stock to employees exercising stock options and from employee payroll withholdings for our 2004 employee stock purchase plan.  This generation of cash from issuance of stock was offset by $900,000 used to acquire treasury stock.  In addition, we used $400,000 for

 

19

 

scheduled payments on capital leases and other fixed-rate debt.  There was no net activity under our credit facility, as we began and ended the quarter with no outstanding balance.

 

Credit Facility:

Option Care signed a $60 million senior secured credit facility with JP Morgan Commercial Finance Corp on March 29, 2002.  Borrowing availability under this facility is related to percentages of our outstanding accounts receivable and inventory balances, less certain ineligible amounts, as defined in the facility agreement.  The agreement requires us to comply with various financial covenants. The JP Morgan credit facility expires on March 29, 2005.  As stated above, we had no outstanding balance under this facility as of March 31, 2004 or December 31, 2003.  We had borrowing availability of approximately $38.4 million as of March 31, 2004 and $37.7 million as of December 31, 2003 based on our accounts receivable and inventory balances on those dates.

 

On October 23, 2003, Option Care and JP Morgan Commercial Finance Corp signed an amendment to the Credit and Security Agreement to address the $6.8 million special provision for doubtful accounts recorded in the quarter ended September 30, 2003 related to our Texas accounts receivable.  The amendment allows Option Care to exclude the $6.8 million charge when calculating our fixed charge coverage ratio in the current and subsequent quarters.  This change in calculation method allowed Option Care to remain in compliance with our financial covenants for the quarters ended September 30, 2003 and December 31, 2003.  We were in compliance with our financial covenants for the quarter ended March 31, 2004 exclusive of this amendment.

 

Accounts Receivable:

The following table sets forth information regarding our accounts receivable as of the dates indicated (dollar amounts in thousands):

 

 

(1)          DSO is calculated using the exhaustion method based on accounts receivable net of allowance for doubtful accounts, and considers only our specialty pharmacy service line and infusion and related healthcare services line.

 

Our accounts receivable, net of bad debt reserves, was $65.7 million as of March 31, 2004 compared to $62.2 million as of December 31, 2003.  This increase in accounts receivable was related to our increase in sequential quarterly revenue, which grew from $95.7 million in the quarter ended December 31, 2003 to $103.1 million in the quarter ended March 31, 2004.

 

20

 

The following table sets forth the percentage breakdown of our trade accounts receivable by aging category and by major payor as of the dates indicated:

 

 

(2)          Accounts receivable by aging category considers only accounts of our specialty pharmacy service line and infusion and related healthcare service line.

 

Our days sales outstanding (DSO) declined to 57 days as of March 31, 2004 compared to 61 days as of December 31, 2003.  Continued billing and collections performance improvements were responsible for the improvement, as well as our continuing growth of specialty pharmacy services revenue, which has a shorter collection cycle than infusion pharmacy and our other related healthcare services.

 

As of March 31, 2004, we had cash and cash equivalents of approximately $6.6 million, an increase of $2.7 million over the balance at December 31, 2003.  Strong operating cash flows allowed us to increase our cash reserves even though we used $1.1 million in cash for acquisitions and another $900,000 to buy treasury stock during the period.  We believe that cash flow from operations and amounts available under our revolving credit facility will be sufficient to meet our operating cash needs for the immediate future, including any interest due on our credit facility or other debts.  In the event that additional capital is required, management cannot assure that such capital can be obtained from other sources on terms acceptable to us, if at all.

 

Our business strategy includes the selective acquisition of additional local pharmacy facilities and specialty pharmacy operations.  Accordingly, we may require additional capital in order to complete these acquisitions.  It is impossible to predict the amount of capital that may be required for acquisitions, and there is no assurance that sufficient financing for these activities will be available on terms acceptable to us, if at all.

 

Goodwill and Other Intangible Assets

 

As of March 31, 2004, we had net goodwill and other intangible assets totaling $66.7 million, consisting of $65.7 million of goodwill and $1.0 million of other intangible assets such as non-compete agreements and managed care contracts.  As of December 31, 2003, net goodwill and other intangible assets equaled $66.1 million, consisting of $65.0 million of goodwill and $1.1 million of other intangible assets.  During the quarter ended March 31, 2004, goodwill increased $700,000 as a result of acquisitions completed in January 2004.  Other intangible assets increased $100,000 as a result of these acquisitions, offset by amortization of $200,000 during the quarter.

 

As required by Statements of Financial Accounting Standards No. 142, Goodwill and Other Intangible Assets (SFAS No. 142), we do not amortize goodwill, but test our goodwill for impairment annually each October 1^st, or whenever we identify events or conditions that could potentially result in impairment of our goodwill.  During the quarter ended March 31, 2004, no impairment of goodwill was identified.

 

Regulatory and Other Developments

 

Health Insurance Portability and Accountability Act of 1996 (HIPAA).  To improve the efficiency and effectiveness of the health care system, the Health Insurance Portability and Accountability Act (HIPAA) of 1996, Public Law 104-191, included “Administrative Simplification” provisions that required the Department of Health and Human Services (HHS) to adopt national standards for electronic health care transactions. At the same time, Congress recognized that advances in electronic technology could erode the

 

21

 

privacy of health information. Consequently, Congress incorporated provisions into HIPAA that mandated the adoption of Federal privacy protections for individually identifiable health information.

 

In response to the HIPAA mandate, in December 2000, HHS published a final regulation in the form of the Privacy Rule, which became effective on April 14, 2001. This Privacy Rule set national standards for the protection of health information, as applied to the three types of covered entities: health plans, health care clearinghouses, and health care providers who conduct certain health care transactions electronically. In March 2002, HHS published proposed modifications to the Privacy Rule, to improve workability and avoid unintended consequences that could have impeded patient access to delivery of quality health care. Following another round of public comment, in August 2002, HHS adopted as a final Rule the modifications necessary to ensure that the Privacy Rule worked as intended. Pursuant to the Privacy Rule, as of April 14, 2003, covered entities were required to have standards in place to protect and guard against the misuse of individually identifiable health information. (Small health plans have until April 14, 2004 to implement such standards.) Failure to timely implement these standards may, under certain circumstances, trigger the imposition of civil or criminal penalties.

 

The Privacy Rule establishes a foundation of Federal protections for the privacy of protected health information. The Privacy Rule does not replace Federal, State, or other laws that grant individuals even greater privacy protections, and covered entities are free to retain or adopt more protective policies or practices. Penalties for non-compliance with the Privacy Rule range from a civil penalty of $100 per person, per incident (which can total up to $25,000 per person per year), to criminal penalties, including up to $50,000 and/or one year imprisonment, up to $100,000 and/or five years imprisonment if the offense is committed under false pretenses and up to $250,000 and/or ten years imprisonment for violating a standard with the intent to sell, transfer or use individually identifiable health information for commercial purposes.

 

In addition to regulating privacy of individual health information, HIPAA includes several anti-fraud and abuse laws, extends criminal penalties to private health care benefit programs and, in addition to Medicare and Medicaid, to other federal health care programs, and expands the Office of Inspector General’s authority to exclude persons and entities from participating in the Medicare and Medicaid programs.

 

We have implemented the standards set forth in the Privacy Rule, and these standards were in place on April 14, 2003. We believe that we and all of our franchisees are in compliance with the Privacy Rule or any more stringent federal or state laws relating to privacy.

 

Medicare Prescription Drug, Improvement and Modernization Act of 2003.  The Medicare Prescription Drug, Improvement and Modernization Act of 2003 changes the way in which covered outpatient drugs are reimbursed by the Medicare program. Starting in January 2004, payment for most drugs covered by Medicare will decrease to 85% of the Average Wholesale Price (AWP) determined as of April 1, 2003. Beginning in 2005, reimbursement for non-self administered drugs furnished to patients in conjunction with other Medicare covered services will be set at either 106% of the average sales price (ASP) or through a competitive acquisition program to be phased in beginning in 2006. The competitive acquisitions program will be established by CMS and will enable physicians in designated competitive acquisition areas to purchase drugs through contractors that have successfully bid for that right. Each physician will elect annually whether to obtain drugs through the competitive acquisition program. CMS will re-bid the contracts at least every three years. For infusion drugs administered in connection with covered durable medical equipment (DME), the payment rate generally will continue to be 95% of the AWP as of October 1, 2003, until such drugs are subject to the implementation of the competitive acquisition program discussed above.

 

While the majority of our revenue is reimbursed by managed care organizations and other non-government payors, these changes to the way in which Medicare pays for outpatient drugs and biologicals may have some impact on us or our franchisees. In addition, as CMS implements the ASP model of reimbursement, it may affect our current AWP based reimbursement structure with our managed care customers. If managed care organizations adopt an ASP-based reimbursement model, our future financial position and results of operations could be materially affected by our ability to renegotiate pricing based on the new methodology.

 

ITEM 3.  Quantitative and Qualitative Disclosures About Market Risk

 

We are subject to market risk from exposure to changes in interest rates based on our financing and cash management activities. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage our exposure to changes in interest rates. Although there can be no assurances that interest rates will not change significantly, we do not expect changes in interest rates to have a material effect on income or cash flows in 2004. As of March 31, 2004, our fixed-rate debt was $100,000 and we had no variable rate debt. Since we had no variable rate debt as of March 31, 2004, a one-percent increase in interest rates would have no impact on our annual interest expense.

 

22

 

ITEM 4.  Controls and Procedures

 

We carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, (as defined in Rules 13a-15(e) under the Securities Exchange Act of 1934 (the Exchange Act)) as of March 31, 2004. Based upon that evaluation, the chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective. Disclosure controls and procedures are controls and procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Security and Exchange Commission’s rules and forms.

 

In addition, no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) occurred during the fourth quarter of our fiscal quarter ended March 31, 2004 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

PART II.  OTHER INFORMATION

 

ITEM 1.  Legal Proceedings

 

We are subject to claims and legal actions that may arise in the ordinary course of business. However, we maintain insurance to protect against such claims or legal actions. We are not aware of any litigation either pending or filed that we believe are likely to have a material adverse effect on our results of operation or financial condition.

 

We were named as a defendant in a lawsuit filed on December 31, 2002 in the District Court, Bexar County, State of Texas under the caption Candace Booker, et. al. vs. Option Care, Inc. et. al, No. 2002 CI 18401. Plaintiffs allege that we negligently prepared a prescription resulting in a fatal injury. Plaintiffs seek unspecified compensatory damages. The lawsuit is currently in the discovery stage. We deny, and intend to vigorously defend against, the allegations contained in the complaint. We believe that to the extent a monetary award is rendered against us, that monetary award will fall within the limits of our general and professional liability insurance coverage for that claim.

 

We maintain insurance for general and professional liability claims in the amount of $1 million per claim and $3 million in aggregate, plus $5 million in umbrella coverage. Accordingly, the maximum coverage for a first claim is $6 million and the maximum aggregate coverage for all claims is $8 million. We also require each franchisee to maintain general and professional liability insurance covering both the franchise and us, at coverage levels that we believe to be sufficient. These insurance policies provide coverage on a claims-made or occurrence basis and have certain exclusions from coverage. There can be no assurance that insurance coverage will be adequate to cover claims that may be asserted against us or that adequate insurance will be available in the future at acceptable cost, if at all. To the extent that liability insurance is not adequate to cover liability claims against us, we will be responsible for the excess. Our current professional liability insurance policy contains a $500,000 deductible per claim. Any claims made against us during the term of this policy could have a material adverse effect on our results of operations or financial condition.

 

ITEM 2.  Changes in Securities and Use of Proceeds

 

None.

 

ITEM 3.  Defaults Upon Senior Securities

 

None.

 

ITEM 4.  Submission of Matters to a Vote of Securities Holders

 

None.

 

23

 

ITEM 5.  Other Information

 

None.

 

ITEM 6(a).  Exhibits

 

See Exhibit Index.

 

ITEM 6(b).  Reports on Form 8-K

 

On February 20, 2004, we filed a current report on Form 8-K regarding a press release we issued on February 17, 2004 to announce our earnings for the quarter and year ended December 31, 2003.

 

On February 24, 2004, we filed a current report on Form 8-K containing the transcript of our conference call with investors on February 17, 2004 to announce and discuss our results of operations for the quarter and year ended December 31, 2003.

 

On April 19, 2004, we filed a current report on Form 8-K regarding a press release we issued on April 15, 2004 to announce our anticipated operating results for the quarter ended March 31, 2004.

 

24

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

		OPTION CARE, INC.
Date: May 10, 2004		By:	/s/ Paul Mastrapa
			Chief Financial Officer
			(Principal Accounting Officer and Principal Financial Officer)

 

25

 

EXHIBIT INDEX

 

Exhibit Number
3.1		Certificate of Incorporation of the Registrant, together with Certificate of Amendment thereto filed February 18, 1992. Filed as Exhibit 3(a) to Option Care’s Registration Statement (No. 33-45836) dated April 15, 1992 and incorporated by reference herein.
3.2		Certificate of Amendment to Certificate of Incorporation of the Registrant filed March 25, 1992. Filed as Exhibit 3(c) to Option Care’s Registration Statement (No. 33-45836) dated April 15, 1992 and incorporated by reference herein.
3.3		Certificate of Amendment to Certificate of Incorporation of the Registrant filed with the Delaware Secretary of State on June 18, 2002 and incorporated by reference herein.
3.4		Restated By-laws of the Registrant dated June 1, 1994. Filed as Exhibit 10.5 to Option Care’s Annual Report on Form 10-K for the year ending December 31, 1994 and incorporated by reference herein.
10.1		Intentionally omitted.
10.2		Intentionally omitted.
10.3		Intentionally omitted.
10.4		Intentionally omitted.
10.5		Option Care, Inc. 401(k) Profit Sharing Plan. Filed as Exhibit 10(b) to Option Care’s Registration Statement (No. 33-45836) dated April 15, 1992 and incorporated by reference herein.
10.6		Amendment to the 1992 401(k) Profit Sharing Plan of the Registrant dated January 1, 1996. Filed as Exhibit 10.3(a) to Option Care’s Annual Report on Form 10-K for the year ending December 31, 1997 and incorporated by reference herein.
10.7		Intentionally omitted.
10.8		Form of Franchise Agreement. Filed as Exhibit 10.5 to Option Care’s Annual Report on Form 10-K for the year ending December 31, 1996 and incorporated by reference herein.
10.9		Intentionally omitted.
10.10		Consulting Agreement between the Registrant and EJ Financial Enterprises, Inc. Filed as Exhibit 10(o) to Option Care’s Registration Statement (No. 33-45836) dated April 15, 1992 and incorporated by reference herein.
10.11		Intentionally omitted.
10.12		Intentionally omitted.
10.13		Intentionally omitted.
10.14		Intentionally omitted.
10.15		Intentionally omitted.
10.16		Intentionally omitted.
10.17		Intentionally omitted.
10.18		Intentionally omitted.

 

26

 

10.19		Intentionally omitted.
10.20		Intentionally omitted.
10.21		Intentionally omitted.
10.22		Amendment No. 1 to the Consulting Agreement By and Between EJ Financial Enterprises, Inc. and Option Care, Inc., dated October 1, 1999. Filed as Exhibit 10.30 to Option Care’s Annual Report for the year ended December 31, 1999 and incorporated by reference herein.
10.23		Intentionally omitted.
10.24		2001 Employee Stock Purchase Plan. Filed as Exhibit A to the registrants definitive proxy statement for the 2000 Annual Shareholders Meeting and incorporated by reference herein. *
10.25		Intentionally omitted.
10.26		Participation Agreement between Health Options, Inc. and Option Care, Inc. effective as of June 1, 1997. 2001. Filed as Exhibit 10.26 to Option Care’s Amendment No. 1 to its Annual Report on Form 10-K/A filed September 10, 2001 and incorporated by reference herein.
10.27		Prescription Drug Agreement among Blue Cross and Blue Shield of Florida, Inc., Health Options, Inc. and Option Care, Inc. dated March 8, 2000. Filed as Exhibit 10.27 to Option Care’s Amendment No. 1 to its Annual Report on Form 10-K/A filed September 10, 2001 and incorporated by reference herein.
10.28		Amendment to Participation Agreement between Health Options, Inc. and Option Care, Inc. dated April 1, 2001. **
10.29		Deferred Compensation Plan for certain Executives, effective as of January 1, 2001. **
10.30		Intentionally omitted.
10.31		Intentionally omitted.
10.32		Injectable Drugs Agreement effective as of September 5, 2001 between Health Option, Inc. and OptionMed, Inc.  Filed on October 10, 2001 as Exhibit 10.1 to Form 8-K/A and incorporated herein by reference.
10.33		Credit and Security Agreement, dated March 29, 2002, by and among Option Care, Inc. and the domestic subsidiaries of Option Care party thereto, as Borrowers, the Lending Institutions party thereto, as Lenders, J.P. Morgan Business Credit Corp., as Advisor, and JPMorgan Chase Bank, as Administrative and Collateral Agent and Arranger, and LaSalle Bank National Association, as Co-Agent.  Filed as Exhibit 10.21 to Option Care’s Current Report on Form 8-K filed May 15, 2002 and incorporated by reference herein.
10.34		Employment Agreement between Richard M. Smith and Option Care, Inc., dated May 7, 2003.  Filed as Exhibit 10.34 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2003 and incorporated by reference herein. *
10.35		Employment Offer Letter between Option Care, Inc. and Paul Mastrapa, dated January 18, 2002.  Filed as Exhibit 10.35 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2003 and incorporated by reference herein. *
10.36		Employment Offer Letter between Option Care, Inc. and Joseph P. Bonaccorsi, dated December 31, 2001.  Filed as Exhibit 10.36 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2003 and incorporated by reference herein. *
10.37		Fourth Amendment to Credit and Security Agreement, dated October 23, 2003, by and among Option Care, Inc. and the domestic subsidiaries party thereto, as Borrowers, the Lending Institutions party thereto, as Lenders, J.P. Morgan Business Credit Corp., as Advisor, and JPMorgan Chase Bank, as Administrative and Collateral Agent and Arranger, and LaSalle Bank National Association, as Co-Agent.  Filed as Exhibit 10.37 to our Quarterly Report on Form 10-Q for

 

27

 

		the quarter ended September 30, 2003.
31.1		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Senior Vice President and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certifications of Chief Executive Officer and Senior Vice President and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and Exchange Act Rule 13a-14(b).

 

*                 Management contracts and compensatory plans and arrangements.

**          Portions of this Exhibit are subject to a Confidential Treatment Request pursuant to Rule 24b-2 under the Securities and Exchange Act of 1934, as amended, filed with the SEC on September 10, 2001 and amended October 10, 2001.

 

28